RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Mapping the research landscape of the correlation between radiotherapy and tumor immune microenvironment: A bibliometric analysis.
Mapping the research landscape of the correlation between radiotherapy and tumor immune microenvironment: A bibliometric analysis.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
这项全面的文献计量学分析突出了未来的优先事项,包括探索联合治疗的最佳协同策略、研究时空分辨的免疫机制以及开发预测性生物标志物。这些领域目前正在快速增长,需要进一步研究。
放射治疗(RT)是癌症治疗的基石,不仅直接杀伤肿瘤细胞,还通过重塑肿瘤免疫微环境(TIME)与免疫治疗产生协同效应。然而,针对RT与TIME相互作用的系统性文献计量学分析尚未被探索。
本研究通过Web of Science (WOS) 核心合集分析了截至2024年所有与RT和TIME相关的文献。利用R、VOSviewer和CiteSpace对作者、国家、机构、关键词、共被引参考文献、研究热点和前沿进行了可视化分析。
中国、美国和德国是主要贡献者,分别发表了1,253篇、581篇和162篇论文。Frontiers in Immunology是最活跃的期刊(n = 186)。共现分析确定“放疗”(n = 898)和“免疫治疗”(n = 895)为核心主题,持续关注“CD8(+) T细胞”(引用爆发 = 8.81),并对“NK细胞”的兴趣新兴。时间演变揭示了三个研究阶段:RT免疫调节机制的初步探索(2007-2015),RT联合PD-1/CTLA-4抑制剂的临床验证(2015-2020),以及近期向技术优化(如立体定向RT)、肿瘤类型扩展和安全性管理的多样化发展(2020-2024)。
Radiation therapy (RT) is a cornerstone of cancer treatment that not only directly kills tumor cells but also produces synergistic effects with immunotherapy by remodeling the tumor immune microenvironment (TIME). However, systematic bibliometric analyses of RT-TIME interactions remain unexplored.
This study analyzed all the literature related to RT and TIME from the Web of Science (WOS) Core Collection through 2024. It utilized R, VOSviewer, and CiteSpace to visually analyze authors, countries, institutions, keywords, co-cited references, research hotspots, and frontiers.
China, the United States, and Germany emerged as the leading contributors, with 1,253, 581, and 162 publications, respectively. Frontiers in Immunology was the most active journal ( n = 186). Co-occurrence analysis identified "radiotherapy" ( n = 898) and "immunotherapy" ( n = 895) as core themes, with sustained focus on "CD8(+) T cells" (citation burst = 8.81) and emerging interest in "(nature killer) NK cells." Temporal evolution revealed three research phases: initial exploration (2007-2015) of RT's immunomodulatory mechanisms of RT, clinical validation of RT combined with Programmed Cell Death Protein 1 (PD-1)/ Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) inhibitors (2015-2020), and recent diversification (2020-2024) toward technical optimization (e.g., stereotactic RT), tumor type expansion, and safety management.
This comprehensive bibliometric analysis highlights future priorities, including exploring optimal synergistic strategies for combination therapies, investigating spatiotemporally resolved immune mechanisms, and developing predictive biomarkers. These areas are currently experiencing rapid growth and require further research.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。